Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Ashley McKhann, Laura Moran, Lubbe Wiesner, Florian von Groote-Bidlingmaier, Philip Marzinek, Naadira Vanker, Joseph Yvetot, Samuel Pierre, Susan L Rosenkranz, Susan Swindells, Andreas H Diacon, Eric L Nuermberger, Paolo Denti, Kelly E Dooley
RATIONALE: Observational studies suggest that high-dose isoniazid may be efficacious in treating multidrug-resistant tuberculosis (MDR-TB). However, its activity against Mycobacterium tuberculosis ( M.tb ) with katG mutations (which typically confer high-level resistance) is not established. OBJECTIVE: To characterize early bactericidal activity (EBA) of high-dose isoniazid in patients with tuberculosis caused by katG -mutated M.tb . METHODS: A5312 was a Phase 2A randomized, open-label trial...
April 2, 2024: American Journal of Respiratory and Critical Care Medicine